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rs2282679	 4	 GC	 72608383	 G	 T	 G	 T	 -0.047	 0.013	 13.38	
rs10741657	 11	 Near	CYP2R1	 14914878	 G	 A	 G	 A	 -0.052	 0.012	 18.78	
rs12785878	 11	 Near	DHCR7	 71167449	 T	 G	 G	 T	 -0.056	 0.013	 18.29	












	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.189	 0.148	 1.21	(0.90-1.62)	 0.201	 0.184	 0.106	 1.20	(0.98-1.48)	 0.083	
GBM	 -0.471	 0.261	 0.62	(0.37-1.04)	 0.070	 -0.479	 0.186	 0.62	(0.43-0.89)	 0.010	
Non-GBM	











Estimate	(95%	CI)	 P	value	 Estimate	(95%	CI)	 P	value	
All	Glioma	 0.072	(-0.121-0.264)	 0.466	 -0.001	(-0.019-0.017)	 0.893	
GBM	 -0.097	(-0.272-0.078)	 0.279	 -0.013	(-0.039-0.012)	 0.307	
























































































































































































































































































































































































































	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.207	 0.161	 1.23	(0.90-1.69)	 0.197	 0.200	 0.117	 1.22	(0.97-1.54)	 0.086	
GBM	 -0.509	 0.315	 0.60	(0.32-1.11)	 0.106	 -0.514	 0.225	 0.60	(0.38-0.93)	 0.023	











	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.088	 0.382	 1.09	(0.52-2.31)	 0.817	 0.090	 0.271	 1.09	(0.64-1.86)	 0.741	
GBM	 -0.391	 0.464	 0.68	(0.27-1.68)	 0.400	 -0.392	 0.330	 0.68	(0.35-1.29)	 0.234	











	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.215	 0.161	 1.24	(0.90-1.70)	 0.183	 0.209	 0.115	 1.23	(0.98-1.55)	 0.069	
GBM	 -0.666	 0.319	 0.51	(0.27-0.96)	 0.037	 -0.668	 0.220	 0.51	(0.33-0.80)	 0.003	
Non-GBM	 0.285	 0.344	 1.33	(0.68-2.61)	 0.407	 0.285	 0.244	 1.33	(0.83-2.14)	 0.242	
	
IVW,	inverse-variance	weighted;	MLE,	maximum	likelihood	estimation;	SE,	standard	error;	
OR,	odds	ratio;	CI,	confidence	interval;	GBM,	glioblastoma.	
